Search the Newsreel

Stronger Production, Earnings and Payouts Could Be A Game Changer For Devon Energy (DVN)

M Evo Global Acquisition Corp II Q2 2026: Net income $2.57M, EPS $0.06— 10-Q Summary

M Evo Global (MEVO) shows $304M in Trust and early SPAC results

Evolution Global Acquisition Corp (NASDAQ: EVOX) earns $3.9M on trust interest

Evolution Global Acquisition Corp (EVOX), a SPAC, reported a net income of $3.89 million for the first half of 2026, primarily from $4.27 million in interest earned on its Trust Account investments. The company, which has yet to complete a business combination, maintains $245.48 …

Revolution Medicines (RVMD) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Wednesday, Aug. 5, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Senior Vice President, Corporate Affairs - Ryan AsayChairman and Chief Executive Officer - Mark GoldsmithChief Development Officer - Alan SandlerChief Financial Officer - Jack AndersChief Medical Officer - …

Devon Energy Corp. stock underperforms Wednesday when compared to competitors

Devon Energy Corp. (DVN) shares fell by 1.19% on Wednesday, closing at $44.86, despite a mixed day for the broader stock market. This decline broke a two-day winning streak for the company's stock. The S&P 500 Index saw a 0.26% increase, while the Dow …

Evolution Global Acquisition Corp Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

Handelsbanken Fonder AB Raises Stock Position in Revolution Medicines, Inc. $RVMD

Handelsbanken Fonder AB significantly increased its stake in Revolution Medicines, Inc. (NASDAQ:RVMD) by 243.6% in the second quarter, bringing its total holdings to 212,275 shares valued at $39.8 million. Despite institutional investors owning a substantial 94.34% of the company, Revolution Medicines reported a quarterly …

Un aumento de la producción, los beneficios y los repartos de dividendos podría suponer un punto de inflexión para Devon Energy (DVN)

Evolv Technologies (NASDAQ:EVLV) Posts Quarterly Earnings Results, Misses Expectations By $0.02 EPS

Evoke (LON:EVOK) Issues Quarterly Earnings Results

Evolv Technologies (NASDAQ:EVLV) Shares Down 5.4% After Earnings Miss

Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Evotec SE announced a notification of major holdings, indicating that The Goldman Sachs Group, Inc. has acquired or disposed of shares with voting rights. As of August 6, 2026, Goldman Sachs holds a total of 13.71% of voting rights in Evotec SE, an increase …

Evolution Global Acquisition Corp Reports Q2 2026 10-Q Filing with Key Financial Updates

Evolution Global Acquisition Corp (EVOX) filed its Q2 2026 Form 10-Q report, detailing financial results for the period ending June 30, 2026. The company, a blank-check SPAC, reported a Trust Account balance of $245.48 million, net income of $3.89 million, and a shareholders' deficit …

Devon Energy Corporation (DVN) Stock Forecasts

Devon Energy (DVN) is an oil and gas producer primarily in the Permian Basin, with significant holdings in other US shale plays. A recent Morningstar report indicates solid results following its merger with Coterra, leading to the maintenance of its valuation. The report provides …

Revolution Medicines hits $44B market cap with breakthrough RAS cancer drugs, attracting big pharma interest.

Revolution Medicines has achieved a $44.1 billion market cap, driven by its promising RAS-targeting oncology pipeline, despite having no current product revenue. The company's drug, daraxonrasib, has shown strong clinical results, particularly in improving survival for pancreatic cancer patients. This success makes Revolution Medicines …

Why Revolution Medicines May Be Big Pharma’s Next Takeover Target

Revolution Medicines (NASDAQ:RVMD) is highlighted as a potential acquisition target for big pharma due to its strong late-stage RAS(ON) oncology pipeline, particularly daraxonrasib's impressive pancreatic cancer data. Merck (NYSE:MRK) is identified as the most likely acquirer, driven by the impending patent cliff for its …

Revolution Medicines (RVMD) Stock Looks Strong On Returns But Expensive On Value

Revolution Medicines (RVMD) has shown strong shareholder returns over the past five years, but its current valuation appears expensive based on broader checks. The stock trades at a high Price-to-Book ratio compared to its industry and peers, suggesting it may be overvalued despite excitement …

Revolve Group (NYSE:RVLV) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Tema ETFs LLC Sells 26,443 Shares of Revolution Medicines, Inc. $RVMD

Tema ETFs LLC has reduced its stake in Revolution Medicines, Inc. by 26.9%, selling 26,443 shares but still retaining 71,735 shares valued at $13.4 million. Despite this, institutional investors collectively own 94.34% of the company, and analyst sentiment remains largely positive with a "Moderate …

HC Wainwright Weighs in on Gevo's Q3 Earnings (NASDAQ:GEVO)

Transcript : Evoke plc, H1 2026 Earnings Call, Aug 12, 2026

Revolution Medicines (RVMD) Stock Looks Rich On Fresh RAS Drug Demand

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Revolution Medicines has delivered a very large 5 year return that leaves the stock looking expensive on Simply Wall St's valuation checks. The current move …

Devon Energy Corp (DVN) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Devon Energy Corp (DVN), detailing its current price momentum score, support and resistance levels, and various technical indicators. It outlines specific buy, sell, and neutral signals from indicators like MACD, RSI, and moving averages, concluding with an …

Evoke H1 Earnings Call Highlights

Key Points Interested in Evoke plc? Here are five stocks we like better. First-half revenue was resilient, but profitability declined: Group revenue was £888 million, up 2% like-for-like, while adjusted EBITDA fell 10% to £150 million as higher gaming duties created a £46 million …

Revolution Medicines’ 486% year leaves volume as the weak spot near the high

RVMD closed just 0.4% below its 52-week high after a 9.4% weekly gain, but participation remained light at 0.7x its 13-week average.

Assenagon Asset Management S.A. Grows Stock Holdings in Evolus, Inc. $EOLS

Assenagon Asset Management S.A. significantly increased its stake in Evolus, Inc. (NASDAQ:EOLS) by 51.8% in the second quarter, now holding 908,180 shares valued at approximately $6.3 million. This move is part of a trend among institutional investors, who collectively own 90.69% of Evolus stock. …

Devon Energy Corporation (NYSE:DVN) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

Devon Energy Corporation (NYSE:DVN) has received a consensus "Moderate Buy" rating from thirty brokerages, with an average 12-month price target of $59.72, significantly above its current share price of $45.37. The company recently reported strong quarterly results, with EPS of $1.57 and revenue of …

Revolution Medicines (RVMD) Is Up 6.2% After BeOne-Funded Phase 3 RAS(ON) Deal - Has The Bull Case Changed?

In early August 2026, BeOne Medicines Ltd. and Revolution Medicines, Inc. announced a multi-part collaboration combining BeOne's oncology assets with Revolution's four clinical RAS(ON) inhibitors, alongside a regional licensing deal granting BeOne exclusive development and commercialization rights in select Asian markets and responsibility for …

Earnings Flash (EVOK.L) Evoke PLC Posts H1 Loss GBX-15.6

REG - Evoke PLC - H1 2026 Interim Results

Revolution Medicines (RVMD) Looks Fairly Valued As BeOne Deal Expands Its Asia Reach

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Revolution Medicines (RVMD) just entered a comprehensive partnership with BeOne Medicines that combines joint clinical development work and a regional rights deal in …

William Blair Investment Management (RVLV) discloses 5.6% Revolve Group ownership

William Blair Investment Management, LLC has reported a 5.6% beneficial ownership stake in Revolve Group, Inc. (RVLV), as detailed in a Schedule 13G filing. As of June 30, 2026, the firm beneficially owned 2,333,717 shares, with sole voting power over 1,820,565 shares and sole …

Devon Energy (DVN) Q2 2026 Earnings Call Transcript

Key Points Interested in Devon Energy Corporation? Here are five stocks we like better. Devon exceeded Q2 guidance, generating $1.7 billion in adjusted free cash flow while beating targets for oil production, total production, operating costs and capital spending. The company tightened its 2026 …

Revolve (RVLV) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Tuesday, Aug. 4, 2026 at 4:30 p.m. ET CALL PARTICIPANTS SVP of Investor Relations - Erik Randerson Co-Founder and Co-CEO - Mike Karanikolas Co-Founder and Co-CEO - Michael Mente Chief Financial Officer - Jesse Timmermans Full Conference Call …

Evolv Technologies Q2 Earnings Call Highlights

Key Points Interested in Evolv Technologies Holdings, Inc.? Here are five stocks we like better. Evolv Technologies reported strong second-quarter results, with revenue up 34% year over year to $43.8 million, ARR reaching $132.7 million, and adjusted EBITDA more than doubling to $4.4 million. …